Kymera Therapeutics (KYMR) Retained Earnings (2019 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Retained Earnings of -$1.1 billion for Q1 2026, down 38.38% year-over-year from -$1.8 billion in Q1 2025, and down 63155.56% quarter-over-quarter from $1.8 million in Q4 2025.
Kymera Therapeutics (KYMR) Retained Earnings (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Retained Earnings for 8 consecutive years, with -$1.1 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 38.38% year-over-year to -$1.1 billion; the TTM figure through Mar 2026 stood at -$1.1 billion (down 38.38% YoY), while the FY2025 annual figure was $1.8 million, up 100.24% from the prior year.
- Retained Earnings retreated to -$1.1 billion in Q1 2026 per KYMR's latest filing, from $1.8 million in the prior quarter.
- Across five years, Retained Earnings topped out at $1.8 million in Q4 2025 and bottomed at -$1.1 billion in Q1 2026.
- Historically, Retained Earnings has averaged -$424.6 million across 5 years, with a median of -$383.8 million in 2022.
- Annual changes were most pronounced in 2022 — Retained Earnings plunged 58050.0% — and 2025, when it soared 113.29%.
- Kymera Therapeutics' Retained Earnings stood at -$383.8 million in 2022, then slumped by 38.29% to -$530.8 million in 2023, then sank by 42.18% to -$754.6 million in 2024, then jumped by 100.24% to $1.8 million in 2025, then slumped by 63155.56% to -$1.1 billion in 2026.
- Business Quant data shows KYMR's Retained Earnings at -$1.1 billion in Q1 2026, $1.8 million in Q4 2025, and -$979.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - | -1.20 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.20 Bn |
| Mar 31, 2026 | -1.14 Bn |
| Dec 31, 2025 | 1.80 Mn |
| Sep 30, 2025 | -978.98 Mn |
| Jun 30, 2025 | 279,000.00 |
| Mar 31, 2025 | -820.19 Mn |
| Dec 31, 2024 | -754.61 Mn |
| Sep 30, 2024 | -683.90 Mn |
| Jun 30, 2024 | -2.10 Mn |
| Mar 31, 2024 | -579.30 Mn |
| Dec 31, 2023 | -530.75 Mn |
| Sep 30, 2023 | -2.45 Mn |
| Jun 30, 2023 | -3.64 Mn |
| Mar 31, 2023 | -424.70 Mn |
| Dec 31, 2022 | -383.79 Mn |
| Sep 30, 2022 | -348.93 Mn |
| Jun 30, 2022 | -305.92 Mn |
| Mar 31, 2022 | -265.67 Mn |
| Dec 31, 2021 | -660,000.00 |
| Sep 30, 2021 | -195.10 Mn |